asia
sinc
end
influenza
viru
rapidli
emerg
mexico
april
team
pip
mortal
rate
southeast
asia
back
frighten
mortal
statist
spark
develop
refin
nation
pandem
prepared
plan
health
udo
includ
stockpil
antivir
henc
degre
societi
prepar
pandem
direct
consequ
loom
threat
grow
problem
influenza
resist
amantadin
rimantadin
influenza
antivir
avail
prior
new
millennium
de
clercq
help
spur
develop
two
novel
antivir
relenza
tamiflu
fig
relenza
zanamivir
develop
biota
hold
manufactur
distribut
glaxosmithklin
first
antivir
new
influenza
antivir
class
call
neuraminidas
inhibitor
nai
approv
treatment
influenza
unit
state
second
drug
class
tamiflu
oseltamivir
carboxyl
develop
gilead
distribut
hoffmannla
roch
fig
also
approv
therapeut
use
unit
state
nation
choos
develop
influenza
antivir
stockpil
chose
tamiflu
fig
major
contribut
reason
prefer
tamiflu
relenza
speak
directli
unit
kingdom
decis
stockpil
tamiflu
lieu
relenza
familiar
peopl
consum
capsul
pill
oppos
disc
inhal
use
administ
relenza
scientif
fig
timelin
major
influenza
strain
span
time
domin
globe
nicol
pandem
influenza
advisori
committe
risk
underor
misdos
use
disc
inhal
seen
major
barrier
relenza
especi
patient
find
hard
breath
andor
asthma
howev
relenza
recogn
appropri
children
renal
insuffici
pregnant
women
scientif
pandem
influenza
advisori
committe
addit
stockpil
relenza
seen
appropri
prepar
possibl
emerg
tamiflu
resist
relenza
also
plan
use
prevent
treat
influenza
frontlin
health
worker
earliest
outset
tamiflu
resist
emerg
scientif
pandem
influenza
advisori
committe
balanc
factor
unit
kingdom
acquir
suffici
stockpil
tamiflu
treat
popul
includ
prophylaxi
therapeut
prescript
antivir
stockpil
increas
cover
popul
outset
pandem
fig
antivir
seen
import
tool
within
pandem
prepared
plan
limit
morbid
mortal
preexposur
prophylax
dose
implement
prevent
infect
individu
expos
infect
contact
postexposur
prophylaxi
dose
implement
prevent
infect
individu
expos
infect
contact
clinic
benefit
acquir
antivir
treatment
maxim
given
within
h
symptom
onset
notabl
reduc
time
symptom
allevi
roughli
half
day
increas
day
case
influenza
confirm
laboratori
test
team
pip
earli
treatment
nai
compar
late
treatment
significantli
reduc
mortal
hospit
patient
team
pip
antivir
prophylaxi
effect
prevent
laboratoryconfirm
influenza
initi
within
h
initi
contact
team
pip
evid
clearli
support
widespread
use
antivir
much
popul
could
afford
benefit
societi
could
enhanc
sever
pandem
combin
use
postexposur
prophylaxi
school
closur
use
antibiot
therebi
reduc
clinic
attack
rate
ie
percentag
whole
popul
becom
infect
stage
pandem
case
fatal
ratio
ie
percentag
becom
ill
subsequ
die
direct
result
ill
event
influenza
viru
acquir
reduc
suscept
tamiflu
expect
challeng
would
met
increas
dose
scientif
pandem
influenza
advisori
committe
henc
dose
would
increas
recommend
dose
treatment
mg
twice
daili
day
prophylaxi
dose
mg
daili
day
dose
determin
empir
pandem
event
antivir
resist
seen
emerg
nai
may
coadminist
scientif
pandem
influenza
advisori
committe
howev
occur
fortun
consider
specul
academ
commun
rais
efficaci
nai
whether
reflect
suffici
valu
money
jefferson
doshi
howev
evid
review
uk
depart
health
write
research
find
sinc
pandem
offer
retrospect
endors
uk
use
nai
increas
weight
evid
favour
stockpil
futur
pandem
team
pip
henc
expect
absenc
innov
influenza
antivir
similar
stockpil
exist
ahead
futur
influenza
pandem
assum
suffici
warn
fortun
enough
last
pandem
emerg
point
literatur
extent
secondari
bacteri
infect
ie
bacteri
pneumonia
contribut
overal
death
rate
pandem
role
like
play
futur
pandem
brundag
shank
gupta
et
al
rate
secondari
bacteri
pneumonia
among
patient
admit
hospit
influenza
vari
team
pip
influenza
infect
predispos
secondari
bacteri
infect
due
combin
respiratori
mucos
damag
reduc
capac
mount
immun
respons
bacteri
invas
team
pip
bacteri
pneumonia
usual
easili
treat
cours
antibioticsa
luxuri
nt
exist
latter
half
centuri
evid
prior
pandem
strongli
support
use
nai
antivir
appar
literatur
likelihood
requir
antibiot
reduc
antivir
given
within
h
appear
symptom
team
pip
henc
increas
use
antivir
would
lead
potenti
reduct
bacteri
pneumonia
would
translat
reduct
antibiot
use
compar
pandem
without
use
antivir
uk
pandem
prepared
plan
recommend
stockpil
antibiot
felt
drug
alreadi
high
use
alreadi
plenti
suppli
lim
prior
pandem
influenza
antivir
frequent
prescrib
influenza
selflimit
diseas
decis
use
novel
drug
pandem
present
novel
ecotoxicolog
challeng
singer
et
al
determin
quantiti
antivir
use
develop
scenario
potenti
effect
within
wast
water
system
wider
environ
becam
focu
subsequ
research
late
present
day
unlik
antivir
antibiot
constant
use
throughout
world
one
might
conclud
given
widespread
use
antibiot
increas
prescript
order
might
pose
neglig
increas
ecotoxicolog
risk
sewag
work
oper
ecosystem
servic
wider
river
environ
hand
given
primari
mode
action
antibiot
inhibit
death
bacteria
would
reason
assum
concentr
antibiot
one
might
wit
loss
microorgan
perform
essenti
function
sewag
work
wider
environ
ie
tip
point
loss
key
bacteria
increas
antibiot
use
pandem
remain
main
ecotoxicolog
concern
pandem
usag
antibiot
antibiot
persist
say
antibiot
consum
excret
biolog
activ
form
tabl
essenti
true
antivir
tabl
except
tamiflu
prodrug
upon
consumpt
approxim
tamiflu
convert
activ
antivir
oseltamivir
carboxyl
remain
leav
fece
unchang
consider
uncertainti
regard
remov
rate
one
drug
one
sewag
work
one
time
expect
antibiot
antivir
would
reach
sewag
work
pass
right
rel
minim
loss
jain
et
al
antivir
particular
seen
highli
resist
biodegrad
prass
et
al
photodegrad
et
al
fick
et
al
realist
assum
antivir
could
persist
environ
suffici
long
enough
enter
drink
water
system
wang
et
al
drink
water
inspector
nd
model
purpos
predict
realist
worstcas
scenario
common
practic
assum
sewag
work
wider
environ
result
signific
loss
drug
within
first
h
sever
question
aris
consid
use
fate
drug
use
pandem
drug
persist
sewag
system
extent
partit
sludg
remain
aqueou
phase
drug
impact
oper
sewag
work
drug
inhibit
growth
andor
function
microorgan
within
receiv
river
import
integr
function
acut
chronic
toxic
issu
relat
exposur
aquat
organ
environment
relev
concentr
drug
drug
increas
preval
antivir
antibiot
resist
environ
potenti
human
health
impact
drug
pose
threat
drink
water
qualiti
question
address
prior
pandem
singer
et
al
evid
emerg
literatur
suggest
mechan
microbi
biofilm
could
inde
disrupt
exposur
tamiflu
within
sewag
work
singer
et
al
parker
et
al
gut
et
al
ceftriaxon
imipenem
trimethoprim
sulfamethoxazol
metronidazol
erythromycin
roxithromycin
azithromycin
clarithromycin
clindamycin
ciprofloxacin
levofloxacin
continu
slater
et
al
henc
risk
sewag
work
failur
exposur
elev
level
tamiflu
influenza
pandem
remain
theoret
possibl
slater
et
al
extent
sewag
work
fail
remain
next
question
total
failur
treat
raw
sewag
would
mean
releas
untreat
sewag
receiv
river
sourc
drink
water
major
citi
river
thame
london
releas
would
result
loss
fish
sensit
aquat
live
downstream
fail
sewag
work
remain
unclear
likelihood
pandem
quantiti
drug
result
incomplet
treatment
sewag
discharg
river
antibiot
design
biostat
lethal
effect
wide
rang
microorgan
thu
capabl
inhibit
growth
function
microorgan
sewag
work
degre
inhibit
could
would
observ
remain
unclear
numer
complic
factor
make
predict
inhibit
microorgan
sewag
work
base
antibiot
concentr
extrem
difficult
determin
sewag
work
receiv
rel
high
concentr
broad
mix
antibiot
time
singer
et
al
constant
influx
drug
antibioticresist
microorgan
sewag
work
contribut
resili
sewag
work
much
contribut
risk
failur
ofloxacin
moxifloxacin
tamifluprodrug
tamifluact
zanamivir
amantadin
rimantadin
total
excret
includ
biolog
activ
chemic
found
urin
fece
case
parent
chemic
oseltamivir
phosphat
metabolis
activ
antivir
remain
parent
chemic
activ
antivir
oseltamivir
carboxyl
excret
releas
activ
antivir
tamiflu
oseltamivir
carboxyl
receiv
river
world
potenti
select
antivir
resist
wildfowl
cohabit
sewageimpact
river
singer
et
al
fick
et
al
wildfowl
attract
nutrientrich
warm
sewag
outflow
expos
rel
high
environment
concentr
tamiflu
coloc
wildfowl
tamiflu
mean
risk
avian
influenza
viru
natur
found
mani
wildfowl
develop
tamiflu
resist
concentr
tamiflu
predict
present
highli
sewageimpact
river
unit
kingdom
expect
suffici
high
select
tamifluresist
gene
avian
influenza
would
ultim
increas
risk
next
pandem
influenza
strain
contain
tamifluresist
gene
gillman
et
al
orozov
et
al
applic
ozon
sewag
effluent
would
potenti
reduc
load
antivir
releas
environ
azuma
et
al
howev
rel
sewag
treatment
plant
util
treatment
option
particularli
unit
kingdom
owe
high
cost
energi
requir
option
mitig
identifi
risk
avail
time
littl
chang
sinc
pandem
summari
influenza
viru
offici
call
gener
rel
small
number
fatal
compar
sever
pandem
like
spanish
flu
meant
medic
respons
proportion
lower
would
expect
moder
sever
influenza
pandem
henc
neg
effect
sewag
work
function
ecosystem
servic
appar
lack
evid
ecotoxicolog
effect
might
much
fact
research
commun
lookingmonitor
effect
low
pathogen
pandem
influenza
strain
influenza
pandem
remain
case
studi
pandem
larg
quantiti
pharmaceut
deploy
worldwid
within
short
time
frame
one
would
forgiven
think
pandem
rare
howev
one
time
least
one
ongo
depend
one
character
pandem
sever
right
mani
wellknown
diseasecaus
pathogen
caus
epidem
pandem
cholera
typhoid
tuberculosi
malaria
hiv
mer
sar
ebola
chikungunya
zika
viru
pathogen
prone
go
pandem
reason
explain
other
despit
perfectli
suit
pandem
yet
go
beyond
epidem
level
follow
discuss
intend
rais
awar
epidem
pandem
risk
variou
highprofil
human
pathogensspecul
pandem
might
developand
highlight
current
treatment
option
cholera
caus
bacterium
vibrio
cholera
transmit
unsaf
water
often
contamin
fece
other
suffer
carri
bacterium
seven
separ
pandem
sinc
sever
notabl
outbreak
cholera
sinc
treatment
cholera
includ
antibiot
doxycyclin
azithromycin
often
necessari
rehydr
strategi
employ
unlik
cholera
anyth
epidem
look
forward
avail
antibiot
longer
limit
suboptim
hygien
water
treatment
standard
often
improv
given
adequ
infrastructur
biggest
risk
cholera
typic
follow
major
loss
critic
infrastructur
loss
water
sanit
follow
natur
disast
earthquak
sever
storm
tsunami
typhoid
fever
caus
bacterium
salmonella
typhi
transmit
consum
contamin
food
water
persontoperson
contact
treatment
includ
doxycyclin
ciprofloxacin
number
antibiot
typhoid
similar
etiolog
cholera
thu
remain
endem
limit
area
poor
sanit
water
treatment
karkey
et
al
tuberculosi
tb
current
found
everi
countri
world
make
global
pandem
estim
onethird
world
popul
infect
mycobacterium
tuberculosi
repres
lead
infecti
caus
death
worldwid
approxim
million
per
year
tb
spread
person
person
tini
droplet
releas
cough
sneez
mechan
similar
influenza
tuberculosi
one
must
take
antibiot
least
month
sensit
strain
may
treat
one
antibiot
resist
strain
requir
sever
antibiot
includ
isoniazid
rifampin
ethambutol
pyrazinamid
fluoroquinolon
emerg
multidrugresist
tuberculosi
one
highest
prioriti
intern
public
health
continu
loss
antibiot
efficaci
resist
spread
real
threat
multidrugresist
tb
becom
even
sever
public
health
threat
malaria
caus
plasmodium
parasit
transmit
bite
infect
anophel
mosquito
world
health
organ
estim
approxim
million
case
malaria
death
mostli
among
children
age
five
depend
parasit
antimalari
drug
includ
chloroquin
quinin
sulfat
hydroxychloroquin
mefloquin
combin
atovaquon
proguanil
malaron
resist
chloroquin
render
drug
ineffect
recommend
treatment
malaria
current
combin
antimalari
medic
includ
artemisinin
either
mefloquin
lumefantrin
sulfadoxinepyrimethamin
quinin
along
doxycyclin
may
use
artemisinin
avail
malaria
limit
area
anophel
mosquito
live
reproduc
make
wider
spread
diseas
somewhat
limit
howev
rang
mosquito
vector
expand
chang
climat
increas
risk
region
might
previous
free
malaria
human
immunodefici
viru
hiv
caus
acquir
immunodefici
syndrom
aid
current
pandem
state
approxim
million
peopl
live
hiv
global
million
death
hivaid
hiv
transmit
person
person
sexual
contact
blood
pregnanc
child
sever
antihiv
drug
nonnucleosid
revers
transcriptas
inhibitor
disabl
protein
need
hiv
replic
efavirenz
etravirin
nevirapin
nucleosid
nucleotid
revers
transcriptas
inhibitor
forc
hiv
make
faulti
copi
abacavir
combin
emtricitabinetenofovir
truvada
lamivudinezidovudin
combivir
proteas
inhibitor
disabl
requir
protein
product
atazanavir
darunavir
fosamprenavir
indinavir
entri
fusion
inhibitor
block
hiv
entri
target
cell
enfuvirtid
maraviroc
integras
inhibitor
prevent
hiv
integr
genom
cell
raltegravir
elvitegravir
dolutegravir
use
drug
suffici
high
among
frequent
recov
drug
wast
water
countri
heavili
impact
hivaid
reach
concentr
mgl
k
orej
et
al
orej
et
al
implic
high
concentr
antivir
environ
potenti
drink
water
yet
studi
middl
east
respiratori
syndrom
coronaviru
merscov
first
discov
saudi
arabia
merscov
sever
disrupt
respiratori
function
lead
pneumonia
short
breath
cough
fever
juli
merscov
case
report
countri
base
recent
world
health
organ
data
report
case
result
death
cur
treatment
merscov
symptomat
treatment
includ
convalesc
plasmacontain
merscov
antibodi
ie
blood
patient
rais
antibodi
merscov
publich
health
england
lopinavir
antiretrovir
proteas
inhibitor
class
nearli
bound
plasma
protein
coadminist
lopinavir
ritonavir
known
highli
activ
antiretrovir
therapi
haart
also
use
treat
hivaid
fact
merscov
easili
transmiss
limit
treatment
option
make
seriou
pandem
risk
sever
acut
respiratori
syndrom
sar
viral
respiratori
diseas
caus
sar
coronaviru
symptom
nearli
ident
influenza
sar
zoonosi
like
origin
infect
bat
sold
food
china
sinc
found
sever
mammal
sar
infect
come
high
risk
secondari
infect
pneumonia
sar
emerg
month
infect
peopl
caus
death
countri
antibiot
ineffect
sar
viral
diseas
much
like
treatment
influenza
antibiot
would
employ
treat
bacteri
pneumonia
much
like
merscov
sar
maintain
high
pandem
risk
ebola
filoviru
caus
sever
hemorrhag
fever
fatal
rate
often
near
transmiss
occur
contact
infect
bodi
fluid
blood
massiv
epidem
ebola
spread
three
west
african
countri
guinea
liberia
sierra
leon
earli
result
case
death
earli
recent
research
indic
potenti
broadspectrum
antivir
rna
virus
rna
polymeraseinhibit
molecul
call
immucillina
adenosin
analogu
incorpor
grow
viral
rna
strand
prevent
rna
synthesi
therefor
viral
replic
biocompat
drug
make
potenti
risk
impact
environment
organ
drug
excret
intact
eas
ebola
transmit
difficulti
treat
infect
make
ebola
seriou
pandem
threat
chikungunya
rna
viru
alphaviru
genu
caus
estim
million
infect
year
diseas
caus
sudden
onset
fever
accompani
joint
pain
last
week
year
fewer
infect
individu
die
diseas
mostli
elderli
underli
chronic
medic
problem
viru
frequent
transmit
human
human
within
blood
carri
infect
aed
albopictu
aed
aegypti
mosquito
number
anim
reservoir
viru
includ
monkey
bird
cattl
rodent
contrast
dengu
primat
host
treatment
chikungunya
fever
joint
pain
remain
vaccin
diseas
transmiss
chikungunya
requir
mosquito
vector
remain
constrain
geograph
rang
mosquito
vector
howev
still
reach
pandem
level
rang
vector
quit
substanti
kraemer
et
al
dengu
rna
viru
genu
flaviviru
transmit
via
aegypti
albopictu
ident
chikungunya
human
human
blood
meal
dengu
found
primat
origin
sourc
dengu
viru
symptom
dengu
includ
high
fever
headach
vomit
muscl
joint
pain
characterist
skin
rash
incid
dengu
increas
fourfold
last
year
licens
therapeut
avail
treatment
dengu
sever
antivir
investig
efficaci
treat
dengu
includ
balapiravir
celgosivir
chloroquin
howev
none
shown
benefici
effect
viremia
clinic
outcom
yacoub
et
al
inabl
control
daybit
anthropophil
mosquito
main
reason
global
spread
dengu
yacoub
et
al
promis
avenu
break
transmiss
cycl
dengu
infect
mosquito
intracellular
bacterium
reduc
viral
replic
mosquito
yacoub
et
al
viru
relianc
geograph
restrict
mosquito
vector
limit
infect
live
visit
tropic
environ
kraemer
et
al
despit
limit
rang
dengu
common
countri
infect
million
peopl
worldwid
year
lead
half
million
hospit
zika
rna
viru
genu
flaviviru
first
emerg
zika
forest
uganda
recent
emerg
french
polynesia
take
center
stage
among
seriou
emerg
public
health
issu
america
transmit
south
america
viru
transmit
mosquito
chikungunya
dengu
virus
typic
caus
rel
minor
ailment
rash
fever
headach
within
week
bitten
mosquito
viru
spread
countri
america
earli
possibl
link
microcephali
unborn
fetus
put
rel
minor
viral
infect
center
stage
vaccin
viru
antivir
report
effect
zika
one
must
assum
experiment
treatment
use
treat
dengu
chikungunya
test
efficaci
relat
viru
zika
viru
arguabl
cusp
consid
global
pandem
risk
increas
case
transmiss
via
sexual
contact
therebi
forgo
otherwis
geograph
limit
mosquito
vector
fact
zika
chikungunya
dengu
malaria
spread
mosquito
introduc
anoth
strategi
combat
diseas
use
insecticid
unlik
pharmaceut
must
prescrib
control
clinic
set
insecticid
use
truli
stagger
quantiti
larg
area
remain
seen
implic
human
health
environ
recent
campaign
spread
zika
viru
particularli
run
summer
olymp
game
lesson
histori
ddt
indic
inde
consequ
widespread
use
viru
human
health
environ
live
travel
mosquito
vector
rang
urg
use
strongest
mosquito
repel
day
night
henc
expect
amount
deet
picaridin
use
area
increas
substanti
remain
larg
unstudi
consequ
widespread
use
repel
repel
select
insecticidetoler
mosquito
known
increas
use
insect
repel
deet
greatli
increas
concentr
environmenta
alreadi
routin
measur
pollut
river
around
globe
costanzo
et
al
consider
routin
exposur
air
travel
mosquitoinfest
area
insecticid
part
aircraft
disinfect
ie
permethrin
phenothrin
etofenprox
world
health
organ
current
pathogen
report
caus
diseas
human
includ
bacteria
rickettsia
fungi
protozoa
helminth
abund
sourc
human
emerg
pathogen
come
organ
classifi
virus
follow
bacteria
jone
et
al
major
pathogen
speci
caus
diseas
human
zoonot
total
contrast
pathogen
identifi
livestock
domest
carnivor
cleaveland
et
al
although
morbid
mortal
statist
avail
human
pathogen
often
case
pathogen
remain
complet
unquantifi
regard
impact
human
health
realiti
stem
fact
viral
diseas
treat
symptomat
owe
challeng
cost
demonstr
caus
organ
mani
ill
selflimit
undergo
analysi
caus
agent
healthcar
profess
typic
look
known
known
seek
screen
beyond
expect
without
thorough
unbias
surveil
emerg
pathogen
continu
surpris
public
health
servic
also
import
realiz
pandem
infecti
contagi
diseas
may
take
form
chronic
diseas
heart
diseas
diabet
cancer
obes
world
health
organ
monitor
global
pandem
heart
diseas
combat
use
statin
among
wide
rang
drug
statin
use
prevent
main
cardiovascular
event
reduc
risk
acut
myocardi
infarct
cardiovascular
revascular
stroke
cardiovascular
mortal
allcaus
mortal
statin
prescrib
drug
world
hobb
et
al
unlik
episod
pathogen
pandem
noncommunic
diseas
pandem
pose
constant
increas
pollut
threat
environ
human
health
clear
societi
much
gain
wellcoordin
medic
respons
pandem
like
agre
thorough
coordin
medic
respons
pandem
prefer
applic
precautionari
approach
potenti
real
effect
chemic
critic
infrastructur
wider
environ
howev
even
nearli
agre
human
priorit
wider
environ
preclud
societi
understand
actual
risk
determin
whether
anyth
done
mitig
perceiv
threat
